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Antiretroviral Resistance Testing
Here and Now
David Paar, MD*, Director, AIDS Care and Clinical
Research Program, University of Texas Medical Branch at
Galveston
Frederick L. Altice, MD**, Editor, HEPP News

Only a few short years ago, viral load (HIV-1
RNA) testing was introduced as a new tool for
HIV management. Many physicians, inside corrections as well as outside, delayed implementing the test. Though most of the arguments
against its use included lack of standardization,
inability to process specimens and shortage of
specialists to interpret and utilize results in HIV
management, the major unspoken obstacle was
cost. In 2000, we now face a similar situation
with antiretroviral resistance testing. Despite
national guidelines for their use as the community standard of care in the US and favorable
retrospective and prospective data, few correctional systems have embraced genotypic or
phenotypic testing. This article will address specific issues in the use of resistance testing and
provide an overview of clinical studies and
potential application for their use.
Defining Resistance: The Causes
of Viral Rebound
The presence of antiretroviral resistance to HIV
medications may be signaled clinically by the
observation of viral rebound. Viral rebound can
be defined as any reproducible increase in the
viral load determined to be threefold or greater
that is not due to acute intercurrent infectious illness or vaccination. It is important to note that
not all rebound phenomena are related to drug
resistance. In fact, the most common cause of
rebound is poor adherence. In studies of virologic rebound occurring in patients receiving a
triple combination including a protease inhibitor,
the largest percentage demonstrate no mutations at all, followed by mutations to the nucleoside reverse transcriptase inhibitor and then to
the protease inhibitor.
Resistance is the result of two major characteristics of HIV: 1) its rapid turnover rate; and 2) its
error prone RNA replication process. HIV lacks
a proofreading function that corrects the mistakes in viral replication that result in mutations.
Within a given patient, HIV exists as a combiProvidence, RI 02906

401.863.2180

nation of multiple strains (quasispecies) that
diverge from the original wild-type or unmutated
virus. The quasispecies differ based on
acquired mutations that are passed onto daughter viruses.

The most
common cause
of viral rebound
is poor adherence.
Most mutations that occur naturally in the
course of viral replication result in no effect on
viral susceptibility to ART, while others lead
to death of the virus. In order to cause clinically important resistance, a mutation must:
1) decrease the viral sensitivity to the drug,
2) become the dominant quasispecies because
of increased viral fitness in the setting of selective drug pressure, and 3) provide a competitive
advantage over the wild-type of the virus and
maintain viral replication by preserving enzyme
function. If one of several quasispecies has a
mutation that results in resistance to a specific
drug, then exposure to that drug acts as a
selective pressure that allows the resistant quasispecies to replicate freely while the other quasispecies and wild-type virus that lack the resistance mutation are suppressed. The resistant
quasispecies then becomes the predominant
replicating strain. Clinically, the patient's viral
load increases and treatment fails. The patterns
and types of mutations associated with NRTIs,
NNRTIs and PIs are described in the HIV 101,
page 5.
Continued on page 2
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Resistance Testing...
(continued from page 1)

The key to understanding the limitations of
resistance testing is understanding that
resistant quasispecies become the dominant strain when HAART is being used,
while other forms of the virus are suppressed, including those that might be
resistant to other drugs. That is, resistance
to a given drug may not be detected if the
patient is not taking that drug at the time
that a resistance test is given. Since the
selective pressure that favors replication of
the resistant quasispecies over the susceptible strains has been removed, there may
not be enough of the resistant quasispecies
present to be detected by current resistance assays. Yet the resistant strain will
rapidly re-emerge if the selective pressure
(the drug) is re-instituted. Thus, knowledge
of prior antiretroviral treatment may steer a
clinician away from a drug that might
appear effective when the results of resistance assays are interpreted without knowledge of prior treatment history.
Resistance to drugs may decrease the ability of the virus to replicate, as has been
reported by a number of investigators. Drug
resistance is associated with impaired protease and reverse transcriptase (RT) function and reduced replication capacity. In
one report, Nelfinavir resistant viruses
exhibited many protease cleavage defects
and 70% of Nelfinavir-resistant viruses
showed large reductions in viral replication
(1). In addition, some viruses exhibit hypersensitivity to selected drugs after developing mutations (2).
Genotyping versus
phenotyping
Resistance is measured by two methods:
genotyping and phenotyping. Commercial
assays using both of these methods are
available. For example, TruGene (Visible
Genetics) and ViroSequ (PE Applied
Biosystems) provide genotyping information, and AntiVirogram (Virco) and
PhenoSense (ViroLogic) provide phenotyping information. Genotypic assays provide
information on mutations in the genes coding for reverse transcriptase and protease
that confer drug. Phenotypic resistance is a
direct measure of sensitivity and is similar
to our current antibiotic sensitivity testing
practices. Phenotypic assays rely on
changes in the IC50, the minimum inhibitory concentration of the drug required to
decrease viral replication by 50% in the
particular cellular system used. The emer-
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Table 1. Studies of the Value of Resistance Testing in Creating Successful ART
GENOTYPING STUDIES
STUDY
GART

N
153

PRIMARY ENDPOINT
Change in viral RNA (at wk. 8)

VIRADAPT

108

Change in viral RNA(at wk. 24)

OUTCOME
Decline in viral RNA
Group A: -1.12 log
Group B: -0.52 log
Decline in viral RNA
Group A: -1.15 log
Group B: -0.67 log

PHENOTYPING STUDIES
VIRA 3001

221

Melnick et al.
115

Achieving VL <400 copies/mL
(at wk. 16)

Observed Data:
59% of Group A had VL<400,
42% Group B had <400.

Decline in viral RNA
(at wk. 4, 16)

At 4 wks, decline in viral RNA:
Group A: -1.0 log
Group B: -0.5 log (at wk. 16, no
significant difference)

GENOTYPING, PHENOTYPING AND SOC STUDIES
NARVAL

541

HIV RNA <200 (at wk. 24)

No significant difference

All studies compared regimens based on resistance testing (Group A) versus standard of
care (Group B).

gence of resistance is signaled by a significant increase in IC50 over baseline (3, 4).
Both genotyping and phenotyping are complex technologies that utilize the polymerase chain reaction and other molecular
techniques. They require specialized facilities staffed by well-trained laboratory personnel. Commercial assays using both
methodologies are available, and the turnaround times for results are 1-2 weeks for
genotyping and 2-4 weeks for phenotyping.
It is important to note that a plasma HIV
RNA level above 1,000 copies/mL is necessary for either method to produce reliable
results. Furthermore, neither method can
routinely detect minority quasispecies;
therefore, some resistant strains of virus
may be missed. Although both types of
assays are reproducible, both intra- and
interlaboratory variability may be greater
with genotypic assays. With regard to
interpretation of results, complex mutational patterns detected by genotyping frequently require the interpretation of an
expert whereas the results of phenotypic
assays may be more easily interpreted by
treating physicians. Phenotypic assays
generally cost more than genotypic (3).
Interpreting Genotypic and
Phenotypic Resistance
Assays
Interpretation of genotypic assays requires
not only knowledge of the individual mutations, which confer resistance and crossresistance to drugs within the same class,
but also an understanding of the interac-

tions of multiple resistance mutations. For
example, a single mutation in the protease
gene may confer high-level resistance for
one PI, yet for another, it may require multiple mutations to confer resistance.
However, the phenotypic expression of a
combination of genotypically detected
mutations cannot always be predicted (3).
To address this issue, Virco (Mechelen,
Belgium), a manufacturer of one commercially available genotypic assay, has used a
relational database of over 10,000 clinical
isolates of HIV for which genotypic and
phenotypic results are known, to assign a
"virtual phenotype" to viral isolates based
on mutational patterns. How this virtual
phenotype correlates with response to antiretroviral therapy must be explored with
appropriately designed clinical trials (5).
Interpretation of phenotypic assay results
suffers from a lack of clinical information
regarding correlation of fold increase in
resistance to in vivo activity of the various
antiretroviral drugs. For example, a small
fold increase in resistance to a protease
inhibitor may be overcome by increasing
serum levels of the protease inhibitor (3).
Using Resistance Testing in
Clinical Practice
The DHHS/Kaiser Guidelines (4) for using
antiretroviral agents recommend that resistance assays be used to modify antiretroviral therapy in the setting of virologic failure
during ongoing HAART and in the case of
suboptimal viral suppression after initiating
a new regimen. Resistance testing should
also be considered in antiretroviral naïve
Continued on page 4
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Letter from the Editor
Dear Colleagues,
Hello Alaska! Hello Arkansas! Hello North Dakota! I have just reviewed our list of subscribers, and I
was amazed and humbled by the breadth and depth of the list. We reach more than 2,300 of you in
all 50 states and several countries. You are physicians, nurse practitioners, pharmacists, and AIDS
educators, who work on the front line of HIV care and interface with the HIV-infected inmate. I am
thrilled that so many correctional providers want to be updated on HIV and Hepatitis and I am honored by your trust in this educational newsletter. This publication reaches a great network of correctional healthcare providers, binds us, and weaves us together in a web of influence. Together, we
are making change in correctional HIV care.
Collectively, we care for almost one-fifth of the nations' HIV-infected individuals in correctional clinic
settings. We take care of one-third of the nations' Hepatitis C-infected patients. We see more STDs,
TB, and mental illness than community providers could ever imagine. We do this within the confines
of prison and jail walls, usually at a distance from academic medical centers, and even farther from
easy access to medical technology. Because of our isolation from the community, we must often rely
on our clinical skills to treat and triage patients.
In the 12 years that I've been working as an HIV provider in correctional settings, I've seen - and
heard about - a great deal of change. Correctional HIV care in the U.S. is moving toward, and in
some cases beyond, the community standard. Certain institutions provide an exemplary level of
care. More important, links between prisons and jails and the community are growing. From the
medical perspective, the walls of correctional facilities are becoming more porous; meaning that
medical education and treatment advances are reaching inside, and - perhaps more importantly information about the work we do and our patients in need is reaching the outside world.
This issue marks our second anniversary at HEPP News! In our third year of publication, we pledge
to continue to bring you the latest in HIV and Hepatitis management, written by correctional professionals with hands-on experience providing patient care in correctional facilities.
After reviewing this issue of HEPP News, readers should understand how to incorporate resistance
testing into HIV care, identify when resistant strains of HIV are signaled clinically, list the newest
treatment strategies for Molluscum contagiosum, and describe the latest news on antiretrovirals.
Last but not least, be sure to update your subscriber information - if you'd like to receive the newsletter by email, in pdf format (can be read on all types of computers), please let us know. We can fax
you AND email you the newsletter if you prefer both formats. Dont forget to visit us for online
archives of HEPP News at www.hivcorrections.org.
We love to hear from you and we accept written contributions. Please write, email, fax, or call!
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The editorial board and contributors to HEPP News
include national and regional correctional
professionals, selected on the basis of their
experience with HIV care in the correctional
setting and their familiarity with current HIV
treatment. We encourage submissions, feed-back,
and correspondence from our readership.
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Anne S. De Groot, M.D.
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Antiretroviral
Resistance Testing...
(continued from page 2)

patients with acute HIV infection for whom
treatment is planned. Suppression of viral
replication during acute HIV infection may
favorably alter the long-term course of HIV
infection by allowing the immune system to
develop antiviral responses that are otherwise impaired by unchecked viral replication
during acute infection. This accounts for the
recommendation of resistance testing for
naïve patients with acute HIV infection, but
not for naïve patients with established,
chronic infection.
Studies Reveal Effectiveness
of Resistance Testing
Several prospective studies provide information on the clinical utility of using HIV-1 resistance assays to direct therapy in patients
who are failing an antiretroviral regimen.
See Table 1 pg.2 for a summary. The GART
(6) and VIRADAPT (7) studies used genotypic resistance assays. In the GART study,
at eight weeks, the mean decline in HIV
RNA was significantly greater in the group
whose regimens were based on resistance
testing than in the SOC group (-1.12 log vs.
-0.52 log). Fifty-five percent of those in the
resistance testing-based group had a viral
load <500 copies/ml versus 25% in the SOC
group. In the VIRADAPT study, at six
months, the resistance testing group had a
significantly greater decline in viral load than
the SOC group (-1.15 log v. -0.67 log).
The VIRA 3001 Study (8) and a study reported by Melnick, et al. (9) used phenotypic
resistance assays to direct a change in antiretroviral therapy. Using intent-to-treat

visit HEPP News online at www.hivcorrections.org
analysis in which patients lost to follow up
were counted as failures, the VIRA 3001
Study found no significant difference
between the groups in the primary endpoint.
In an alternative analysis using observed
data, there was a significant difference in the
groups (59% of those in the resistance-testing group had a viral load <400 copies/mL v.
42% in the SOC group, Melnick et al.) At four
weeks, there was a statistically greater
decline in viral RNA in the resistance-testing
group than in the SOC group, but the difference was not sustained at 16 weeks. These
two studies were conducted with participants
who were more highly treatment-experienced than those in GART and VIRADAPT.
Therefore, the number of available active
agents was limited, particularly in the study
reported by Melnick et al. in which even
those on resistance-testing-based-regimens
were on an average of less than three active
drugs. This fact must be taken into account
when interpreting these studies.
In the NARVAL study, 541 (10) highly treatment-experienced patients failing a 3 drug
protease inhibitor containing regimen were
randomized to therapy based either on
genotyping, phenotyping, or SOC. At week
24, a greater percentage of participants in
the genotyping-based group had HIV-1 RNA
levels less than 200 copies/mL, but the difference was not statistically significant.
Although short in duration, GART and
VIRADAPT clearly support the use of resistance assays to help direct antiretroviral
therapy. VIRA 3001 and the study reported
by Melnick, et al. are equivocal, while NARVAL does not support resistance testing.
Because participants in these last three
studies had greater prior treatment experi-
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ence than in GART and VIRADAPT, one
interpretation of these data is that resistance
testing is less useful in highly treatmentexperienced patients with few treatment
options. Thus, one clear indication for use of
resistance testing is after the first regimen
fails.
Conclusion
In summary, the use of both genotypic and
phenotypic resistance assays is expanding
in clinical practice. Although specialized
facilities and personnel are necessary to
conduct these tests, commercially available
kits have made the results reproducible,
available in a timely fashion, and relatively
affordable. Resistance testing to guide modifications in ongoing therapy is recommended in the setting of antiretroviral failure when
a new regimen is anticipated and also in the
setting of incomplete suppression of viral
replication by a new regimen. It should also
be considered when the decision is made to
treat acute HIV infection. Several prospective clinical trials have demonstrated better
suppression of viral replication in patients
whose antiretroviral regimen has been guided by resistance testing, particularly in
patients whose exposure to prior antiretroviral therapy has been limited, i.e. after the
first regimen fails. Despite this benefit, resistance testing information must be combined
with a complete medical history that details
prior regimens, side effects to medications,
and adherence with treatment. Such information is essential in selecting a regimen
that is not only effective in suppressing viral
replication but also acceptable to the individual patient.
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HIV Medications and Gene Mutations
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Primary mutations are those that are associated with high-level resistance to an ART. Secondary mutations include
those that alter conformation such that viral fitness is modified but not high-level resistance. For patients who are sustained on partially suppressive therapy for prolonged time periods, additional compensatory mutations may develop.
This list of primary and secondary mutations for each available ART is listed below. This chart will be updated in future
issues as new information is described.

ANTIRETROVIRAL

1° MUTATIONS

ALL NRTIS

69, 151

Zidovudine (AZT, ZDV)

70, 215

41, 67, 210, 219

Didanosine (DDI)

74

65, 184

Zalcitibine (DDC)

74

65,69,184

Stavudine (D4T)

75

-

Lamivudine (3TC)

184

-

Abacavir (ABC)

184

65, 74, 115

Nevirapine (NVP)

103, 181,190

106,108,188

Delavirdine (DLV)

103, 181

236

Efavirenz (EFV)

103

100,108, 188, 190

Saquinavir (SQV)

48,90

10,54,63,71,73,82,84

Indinavir (IDV)

46,82

10,20,24,32,54,63,71,73,84,90

Ritonavir (RTV)

82

20,32,33,36,46,54,63,71,84,90

Nelfinavir (NLF)

30

36,46,63,71,77,84,88,90

Amprenavir (APV)

50

10,46,47,84

2° MUTATIONS

NNRTIS

PROTEASE INHIBITORS

Amino acid changes in the viral enzyme system are the result of a mutation. Such changes may be in the form of substitutions, insertions or deletions. Mutations are also classified as primary and secondary. Primary mutations typically arise first
in response to therapy with a particular antiretroviral agent. Primary mutations are drug specific and typically interfere with
the binding of the drug to the viral enzyme. The extent to which the mutation alters the binding of the drug to the enzyme
directly influences the reduction in IC50. Secondary mutations accumulate during continued therapy with a given drug and
usually potentiate the effect that the primary mutation had on drug binding. Secondary mutations have a less dramatic effect
on increasing the IC50, however may significantly affect cross-resistance. For instance, if a patient remains on a non-suppressive, PI-containing regimen for considerable time in the setting of a high viral load, the number of secondary mutations
increases and may adversely affect the ability to use another PI in salvage therapy.
The occurrence of cross-resistance has resulted in many clinicians adhering to the concept that the first regimen will be the
most effective regimen or the first shot is the best shot. Therefore clinicians, when possible, should select regimens with a
high genetic barrier for developing resistance. This must be tempered by selecting regimens that are simple and have few
side effects. These competing paradigms often require clinicians to frequently monitor viral load and change regimens quickly after viral rebound to avoid the development of cross resistance. Resistance testing may aid in the decision for altering an
antiretroviral regimen in such settings.

Web Resources
Updated HIV Drug Resistance Testing Guidelines, published by
the International AIDS Society, USA Part II.
http://jama.ama-assn.org/issues/v283n18/full/jst90018.htm
The AIDS Gateway to the Internet
http://www.aids.org
AIDS Medications Information
http://www.aidsmeds.com

UK National AIDS Manual/ British HIV Association
http://www.aidsmap.com
Physicians Research Network
http://www.pnr.org

7th Conference on Retroviruses and Opportunistic
Infections
http://www.retroconference.org
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Treatment
Updates
XIIIth International AIDS
Conference Continued:
The Difficulty of Deep
Salvage
The International Conference on
AIDS is the premier venue for presentation of HIV-related research
from all over the world. The last
issue of HEPP News covered the
prison-related data, and some of the
medical reports. This article will
review the important data regarding
the care of individuals with access
to potent HIV therapies.

An increasingly frequent
conundrum confronting
clinicians is the management
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HEPPigram
When to Genotype in the Management of Drug Resistance
Among HIV-infected Inmates
HIV-Positive Patient

Experienced

Naïve (no previous ART)

Chronic Infection
(>3 years)

Recent Infection
(within 3 years)

Not responding to
HAART,
(VL>1000 copies/mL)

Responding to
HAART,
(VL<1000 copies/mL)

Evaluate and treat
for HIV.
Dont genotype.

HIV source
known?

Adherent?

Continue HAART

Known

Unknown

Yes

No

Source on ART?

Consider
genotyping*

New regimen
available?

Reinforce adherence
and continue to
monitor viral load
and CD4 T-cell
count

No

Yes
No

Yes

of the highly treatmentexperienced patient.
In areas where combination antiretroviral agents have been available, there are still persistent questions regarding the care of the treatment naïve patient as well as the
patient whose treatment meets virologic failure. New data related to
each of these areas could be found
at the conference and, while unexpected or spectacular headlinemaking results were not announced,
several instructive lessons for
providers and patients were presented.
As discussed in the main article, an
increasingly frequent conundrum
confronting clinicians is the management of the highly treatment
experienced patient. Most studies
to date have demonstrated that successful virologic suppression of
such patients is difficult to achieve
regardless of the choice of agents
employed. Aggressive attempts to
regain control of viral replication by
using multiple antiretrovirals in combination, so called 'megaHAART',
have had some better results.
Follow-up data from one of the few
mavens of megaHAART, Julio
Montaner, were presented at
Durban. Overall, using combinations of up to 8 antiretroviral agents
in heavily treatment experienced
patients in Vancouver, approximateContinued on page 7

Evaluate and treat
for HIV if appropriate. (Probably no
need to genotype.)**

Concern about
infection with
resistant virus?

High

Low

Consider
genotyping

Select ART regimen
using drugs the HIV
source did not
receive.

Repeat viral load
measurement

G
G
G

Consider genotyping
Implement regimen
Monitor viral load

VL>1000 copies/mL?
(Necessary for
genotyping to be
carried out.)

Yes

No

*For more information on baseline HIV resistance rates, see 6th Conference on
Retroviruses and Opportunistic Infections,
Abstract 272. www.retrovirus.org/99

Genotype

Continue monitoring
viral load

**For advice on initiating ART in acutely HIVinfected patients, see Carpenter CCJ et al.,
JAMA 1/19/00; 283(3):381-390.

Determine new
regimen

If genotype appears
to leave no options,
consider phenotyping

Important Correction from July/August 2000 issue: in the HEPPigram,
VCG IgG antibody positive patients are immune, contrary to what we printed.
VCG IgG antibody negative patients should follow the remaining path in the
flow sheet.
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Treatment
Updates...

(continued from page 6)

ly 40% of subjects who could tolerate
these intensive regimens had HIV RNA
levels below 400 copies/mL at one year.
As expected, intolerance and toxicity
were high and resistance testing predicted success. MegaHAART remains an
option for select patients for whom treatment cannot wait until the release of new
drugs. However, extreme caution must
be used when combining these agents
to minimize drug interactions and serious toxicity.

For many patients with multiple
antiretroviral experience
and resistance, new drugs offer
the only hope to regain
virologic control.
For many patients with multiple antiretroviral experience and resistance, new
drugs offer the only hope to regain virologic control. One of the most talked
about drugs on the horizon is ABT-378/r
or lopinavir - recently christened with the
trade name Kaletra. This drug is actually a combination of two protease
inhibitors, ABT-378 400 mg plus 100 mg
of ritonavir - the latter, included to
increase plasma concentrations of the
former. Several posters reported on the
potency of this agent including treatment
of multiple drug experienced patients
(TuPeB3196, TuPeB3197, TuPeB3198).
In one study by Clumek et al. of 57 subjects with extensive NRTI and PI experience but who were all NNRTI naïve,
EFV and a NRTI chosen by the investigator plus one of two doses of
lopinavir/ritonavir (400/100 versus
533/133) were studied. In an intent to
treat analysis, 69% of the lower dose
arm and 80% of the higher dose arm
achieved viral loads below 400
copies/mL (TuPeB3196). Additionally,
the drug appears to be effective despite
predicted resistance by genotype and
phenotype testing. Diarrhea and nausea are the major toxicities associated
with lopinavir. The ritonavir component
may present problems for maintenance
of normal blood lipids.
Other new agents discussed at the
conference, which appear promising
include: T-20, an injectable HIV fusion
inhibitor that continues to maintain good
responses out to 48 weeks of study
follow-up and DAPD another guanosine
analog (like ABC) that may actually have
activity against multi-nucleoside resistant virus. (For more information on
the conference and abstracts, visit
www.aids2000.org).
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Ask the Expert
Dr. Feller, of Miriam Hospital and Clinical Professor of Medicine at Brown University,
Providence, contributed the following case. Dr. Feller is a hepatologist who provides expert
consultation to HIV practitioners who wish to treat their HIV and HCV co-infected patients for
Hepatitis C.
HEPP News Expert Case: A 34-year-old male intravenous drug user with well-controlled
AIDS and abnormal alanine transferase is seen in Infectious Disease clinic at the prison.
His T cell count is 250, and he has had several consecutive undetectable viral loads (<50)
by RNA PCR over the past 6 months. His HIV is controlled with DDI, D4T, Efavirenz; he
takes his DDI on his own in the morning (two concentrated formulation 200 mg tablets) and
receives the other two medications by DOT at the medline window.
The ID consultant obtains an HCV antibody test, which is positive. After discussion, it is
clear that the patient will be remaining in prison until his maximum sentencing date two
years hence. He is currently enrolled in a drug "recovery" program at the prison, and he
willingly states that he is committed to a life without drugs and alcohol. He has a history of
depression, and was on serotonin-uptake inhibitors in the past, but he claims that this is
"under control" right now and doesn't want to take any "mood altering drugs" while he's in
the drug recovery program.
A liver biopsy is ordered and approved by the URC after careful review. The biopsy reveals
moderate fibrosis. Combination treatment for HCV with interferon/ribavirin is initiated.
What concerns would you have, as the HCV expert, about his course of treatment?
Dr. Feller: In Rhode Island, as in other state
correctional systems, we've observed a high
prevalence of HCV and HIV co-infection in
incarcerated populations. With highlly active
antiretroviral therapy (HAART) and a subsequent decline in mortality from opportunistic
infections in HIV, hepatic failure is likely to
increase as a leading cause of death in incarcerated patients. Co-infection with HIV raises
particular treatment issues.
For example, we've observed that co-infected patients on combination therapy tend to
have more problems with ribavirin-associated hemolytic anemia and interferon-related
thrombocytopenia than patients who are not
co-infected. Monitoring will detect which
patients develop anemia (hemoglobin <10-11
grams %), that can be treated with erythropoiten at dose of 40,000 units weekly.
Although patients have slightly more difficulty tolerating therapy, HCV treatment does
clear HCV RNA from serum in a portion of
patients who have HIV co-infection, similar to
non co-infected patients.
Occasionally, patients will experience hepatotoxicity when an HIV regimen is instituted.
Treating HCV first to suppress viral activity
may permit the introduction of HIV drugs with
less hepatotoxicity.
Certain HIV treatments are more toxic when
used in combination with HCV. For example,
the protease inhibitor ritonavir is most hepatotoxic, followed by indinavir. Sacquinavir
and nelfinavir are generally better tolerated.
HIV treatment is generally introduced first
because HIV may be more rapidly progressive. At times, severe hepatic disease may
necessitate early HCV therapy, allowing subsequent introductions of HIV drugs with
decreased hepatotoxicity.

Q: What types of HCV treatment-related
issues arise with HIV-infected patients that
are not different from other patients?
Dr. Feller: Interferon-related depression is
real and can be fatal. Should depression
reoccur here, the ID consultant should select
serotonin re-uptake inhibitors, monitor mental status, and not withhold anti-HCV therapy for well-controlled depression.
Q: What findings do you consider "new" and
important for our audience, that might also be
relevant to this case?
Dr. Feller: This patient has moderate fibrosis. He may not completely recover from
HCV infection, however there is recent evidence that some patients who do not clear
HCV-RNA from serum may have interferonrelated improvement in liver fibrosis. Some
research has suggested that even if interferon does not clear the virus, maintenance
therapy may decrease or stabilize hepatic
fibrosis and prevent end-stage cirrhosis.
(See News Flashes on page 8.)
Q: What other concerns exist in the treatment of HCV in HIV-infected patients?
Dr. Feller: Be wary in initiating anti-retroviral
therapy of "immune reactivation" flare up
(HCV patients started on anti-HIV therapy
may get hepatomegaly, upper abdominal
pain, deterioration of liver function). Also
watch for drug hepatotoxicity, and immune
system reconstitution.
For more information on the management of
Hepatitis C, see HEPP News Vol. 3, Issue 6,
June 2000 at http://www.HIVcorrections.org.
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Save the
Dates
United States Conference on AIDS
October 1-4, 2000
Atlanta, GA
Contact: Oscar Medrano, Conference
Registrar, National Minority AIDS
Council, 1931 13th St NW, Washington
DC 20009-4432
Call: 202.483.6622 x 343
E-mail: omedrano@nmac.org or
info@nmac.org
Management of HIV/ AIDS in the
Correctional Setting: A Live
Satellite Videoconference Series,
Antiretroviral Update 2000
October 3, 2000
12:30- 3:30 E.S.T.
2.5 CME credits available
Call: 518.262.6864
Email: santosm@mail.amc.edu
View this talk on your computer!
In November, you'll be able to
visit the HEPP News website at
www.HIVcorrections.org, to
download and view the above video
conference at your convenience.
Thirteenth Annual Conference
Association of Nurses in AIDS Care
Chasing a Changing Tide: Complex
Clients, Care, and Communities
November 2-5, 2000
Caribe Hilton San Juan, Puerto Rico
Contact: Sande Gracia Jones
958 Whitehall Ln.,
Orlando , FL 33019
Call: 305.493.6734
Fax: 305.567.4319
Email: sj394@ starnet.com
http://www.anacnet.org/
anacabstracts.htm
National STD Prevention Conference
December 4-7, 2000
Milwaukee, WI
Contact: Glenda Vaughn, Centers for
Disease Control and Prevention
Call: 404.639.1806
E-mail: ghv1@cdc.gov
Medical Management of AIDS: A
Comprehensive Review of HIV
Management - Winter Symposium
December 7-9, 2000
San Francisco, CA
Contact: Cliff Brock
Department of Medicine UCSF
Box 0656
San Francisco, CA 94143-0656 USA
Call: 415.476.5208
Fax: 415.476.3542
Email: cme@medicine.ucsf.edu
Web: http://medicine.ucsf.edu/
programs/cme
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News Flashes
Treating STDs Could Reduce HIV
Transmission by 27 Percent

Dr. Richard Rothenberg of the Ad Hoc STD/HIV
Transmission Group found that identifying and
treating people who have both HIV and another
sexually transmitted disease (STD) could
reduce the risk of HIV transmission to an uninfected person by 27 percent. Data from eight
clinics across the United States on more than
4,500 HIV- and STD-infected individuals
showed that the decrease in possible HIV transmission ranged from 10 percent in Los Angeles
to 38.1 percent in Colorado Springs. (STD,
August 2000;27:411-416).

Success Against Molluscum
Contagiosum Virus (MCV) Noted

Recently, doctors at the National Cancer
Institute in Bethesda, MD, reported some success against MCV (Molluscum contagiosum
virus) lesions using the antiviral drug cidofovir
(Vistide). MCV can cause disfiguring lesions on
the face, neck and genitals of people with
HIV/AIDS. There is no therapy specifically
licensed by the FDA for the treatment of MCV
lesions, but doctors have used, with varying
degrees of success, the immune boosters
Aldara (imiquimod) and DNCB, liquid nitrogen,
electric "zapping" of lesions and Retin-A. A
recent study reviewed the cases of two young
HIV-infected boys: one 4-year-old (CD4+ count
of 168 and viral load of 430,000 copies), and
one 8-year-old (CD4+ count of 329 and viral
load of >700,000). Despite the fact that both
boys had been receiving HAART for two years,
hundreds of MC lesions had developed on their
bodies. Using a skin treatment consisting of 15
grams of cidofovir with 22.5 grams of Dermovan
ointment, the doctors treated the skin lesions
once daily for five consecutive days each week,
for eight weeks. After two months of cidofovir
therapy the MC lesions cleared and have not
returned after 18 months of monitoring.
(Archives of Dermatology 2000;136:983-985).

Two Important Follow-Ups on HCV
Liver Fibrosis

At the 4th International Workshop on HIV Drug
Resistance and Treatment Strategies, N.
Shulman of Stanford University reported on
"Histologic improvements of liver despite virologic failure of interferon (IFN)+ribavirin therapy
in 3 HIV+/HCV+ patients." Following up from
our Hepatitis C issue in June, this was a reference we could not locate showing the link
between treatment and improved post treatment
liver biopsy regardless of stage of disease. In
an ongoing treatment trial of IFN alpha, 3 million units TIW + ribavirin 800mg/d , 3 patients
with virologic failure at 6 months received preand post-therapy liver biopsies. As has been
shown in HIV- HCV+ patients, treatment of
HCV with interferon-based therapy can lead to
histologic benefits despite lack of HCV clearance or ALT normalization. Biopsy outcomes
should be an important part of future therapeutic trials for these patients.
M Putoi from University of Brescia, Italy, presented "Liver Fibrosis progression is related to
CD4+ cells depletion in patients with Hepatitis C
and Human Immunodeficiency Virus
Coinfection." The relationship between the
stage of liver fibrosis and CD4 levels was analyzed taking into account the variables known or
suspected to influence liver fibrosis progression
by using polytomous logistic regression. The
authors concluded that CD4 cells depletion is
independently associated with the severity of
liver fibrosis in chronic Hepatitis C. Antiretroviral
combination therapy aiming at keeping high
CD4 counts should be regarded as a priority in
the care of HIV and HCV coinfected patients.
(Reports from the 4th International Workshop
on HIV Drug Resistance and Treatment
Strategies, Sitges, Spain, June 12-16, 2000).

Resources & Opportunities
Inmate Adherence Videotape Series:
A Strategy to Increase HIV/AIDS
Medication Adherence in Correctional
Settings

Comprised of five videotapes, this series aims
to increase HIV-infected inmates' awareness of
their disease and treatment with the ultimate
goal of reducing the progression of HIV
observed in correctional medical units.
Additionally, these tapes may encourage cost of
savings for correctional facilities by reducing the
expenses associated with treating preventable
complications of HIV. $40.00. Contact Albany
Medical College at 518/ 262. 6864 or
santosm@mail.amc.edu

Pocket Guide to HIV/AIDS Treatment

is available from the Hopkins HIV Report. The
guide was created for the AIDS Education and
Treatment Center's National Resource Center, a
project sponsored by HRSA. To obtain a copy,
contact your regional AETC, or visit
http://www.aids-ed.org.

A New Treatment Directory through the
National Institutes of Health Clinical Center of
Pharmacology is available at:
http://www.cc.nih.gov/phar
Free CME materials are available through
the Healthcare Consortium
http://www.hivcme.org
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Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of
the questions. A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through
Oct. 31, 2000. The estimated time for completion of this activity is one hour and there is no fee for participation.
1. The 184 mutation confers resistance to which antiretroviral drug?
a) Stavudine (D4T)
b) Zidovudine (ZDV, AZT)
c) Lamivudine (3TC)
d) Nevirapine (NVP)
2. Which of the following HIV antiretrovirals are reported to be welltolerated in the presence of HCV treatment?
a) ritonavir
b) indinavir
c) saquinavir
d) Abacavir
3. In which of the following situtations is resistance testing recommended?
a) For ART naïve patients with established, chronic
infection
b) For ART naïve patients with acute HIV infection
c) In the case of suboptimal viral suppression after
initiating a new regimen
d) a and b
e) b and c
f) None of the above
4. Not all viral mutations cause clinically important resistance to ART.
Which of the following mutations cause clinically significant
resistance?
a) Mutations that become the dominant quasispecies
because of increased viral fitness in the setting of selective
drug pressure
b) Mutations that provide a competitive advantage over the
wild-type of the virus and maintain viral replication by pre
serving enzyme function.
c) Mutations that increase viral sensitivity to the drug
d) a and b
e) all of the above
5. How is the presence of antiretroviral resistance to HIV medications
signaled clinically?
a) reduction in CD4 count
b) any reproducable three fold or greater increase in viral
load in any patient who is adherent
c) Significant increase (VL>50mL) in viral rebound in any
patient who is adherent
d) Significant fluctuation of CD4 count
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6. According to a recent report, which of the following treatments are
FDA approved for use against Molluscum contagiosum?
a) immune boosters Aldara (imiquimod)
b) DNCB
c) electric "zapping" of lesions
d) Retin-A
e) the antiviral drug cidofovir (Vistide)
f) none of the above
g) all of the above

HEPP News Evaluation
5 Excellent

4 Very Good

3 Fair

2 Poor

1 Very Poor

1. Please evaluate the following sections with respect to:
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Updates
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2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?

4. How can HEPP News be made more useful to you?

5. Do you have specific comments on this issue?

CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912

The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor
continuing medical education activities for physicians.

The use of the Brown University School of Medicine name implies review of the educational format and material only. The opinions,
recommendations and editorial positions expressed by those whose input is included in this bulletin are their own. They do not represent or
speak for the Brown University School of Medicine.

For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree
Address

____________________

____________________________________________________________________________________________

____________________________________________________________________________________________________
City

____________________________________________________ State

________ Zip ________________________

Telephone ________________________________________________ Fax ______________________________________

